Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evobrutinib in hepatic impairment
NCT04546789Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Sep 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of evobrutinib (3 arms), sponsored by Merck KGaA. Primary endpoints: Area Under the Plasma Concentration Time Curve From Time Zero to Infinity at 32 hours and Maximum Observed Plasma Concentration at 32 hours. Started Sep 2020; status: completed.
02
Drugs
evobrutinib
Beyond the preview
Go deeper on NCT04546789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04546789.